Table 5.
Prevalent combinations in early- and late-onset ND
| Age of onset | AD | Mixeda | ALS | FTD | Clinical Tau | LBD | MSAa | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EO | LO | LO | EO | LO | EO | LO | EO | LO | EO | LO | EO | |
| Number of combinations | 13 | 16 | 27 | 14 | 15 | 24 | 24 | 14 | 26 | 35 | 30 | 8 |
| ND only (%)b | 44% | 31% | 18% | 75% | 36% | 66% | 41% | 58% | 28% | 35% | 18% | 81% |
| ND + associated (%) | 53% | 69% | 59% | 13% | 28% | 20% | 39% | 21% | 34% | 37% | 47% | 3% |
| ND + ageing (%) | 1% | 1% | 9% | 11% | 36% | 14% | 20% | 21% | 38% | 29% | 35% | 17% |
| Combinationc | ||||||||||||
| A-B-C | 16% | 13% | 10% | – | – | – | – | – | – | – | – | – |
| A-B-C-CAA | 26% | 19% | 11% | – | – | – | – | – | – | – | – | – |
| A-B-C-CAA-CVD | 9% | 10% | 7% | – | – | – | – | – | – | – | – | – |
| A-B-C-LB | 7% | – | 6% | – | – | – | – | – | – | 5% | 19% | – |
| A-B-C-LB-CAA | 16% | 6% | – | – | – | – | – | – | – | – | 8% | – |
| A-B-C-LB-CAA-CVD | – | 5% | – | – | – | – | – | – | – | – | 6% | – |
| A-B-C-TDP | – | 8% | – | – | 13% | – | – | – | – | – | – | – |
| A-B-C-TDP-CAA | 8% | 14% | 7% | – | 6% | – | – | – | – | – | – | – |
| A-B-C-TDP-CAA-CVD | – | 5% | 6% | – | – | – | – | – | – | – | – | – |
| A-B-C-TDP-LB | – | – | 7% | – | – | – | – | – | – | – | 6% | – |
| A-B-C-TDP-LB-CAA | – | 5% | 6% | – | – | – | – | – | – | – | – | – |
| TDP | – | – | – | 75% | 36% | 42% | 29% | – | – | – | – | – |
| TDP-A | – | – | – | – | 9% | – | – | – | – | – | – | – |
| TDP-B | – | – | – | 7% | 6% | 5% | – | – | – | – | – | – |
| Tau | – | – | – | – | – | 24% | 12% | 31% | 32% | – | – | – |
| Tau-A | – | – | – | – | – | – | 8% | – | – | – | – | – |
| Tau-A-B-C | – | – | – | – | – | – | – | – | 6% | – | – | – |
| Tau-A-B-C-CAA | – | – | – | – | – | – | – | – | 6% | – | – | – |
| Tau-A-C | – | – | – | – | – | – | – | – | 8% | – | – | – |
| Tau-A-C-CAA | – | – | – | – | – | – | – | – | 5% | – | – | – |
| Tau-B | – | – | – | – | – | – | 6% | – | 11% | – | – | – |
| Tau-CVD | – | – | – | – | – | – | – | – | 5% | – | – | – |
| Tau-LB | – | – | – | – | – | – | – | 5% | – | – | – | – |
| Tau-TDP | – | – | – | – | – | – | – | – | 8% | – | – | – |
| LB | – | – | – | – | – | – | – | – | – | 35% | 18% | – |
| LB-A | – | – | – | – | – | – | – | – | – | 10% | – | – |
| LB-A-C | – | – | – | – | – | – | – | – | – | 9% | – | – |
| LB-A-C-CAA | – | – | – | – | – | – | – | – | – | – | 6% | – |
| LB-B | – | – | – | – | – | – | – | – | – | 7% | – | – |
| GCI | – | – | – | – | – | – | – | – | – | – | – | 81% |
| GCI-A-C | – | – | – | – | – | – | – | – | – | – | – | 6% |
| Rare combinations | 17% | 15% | 41% | 18% | 30% | 29% | 45% | 64% | 21% | 35% | 39% | 14% |
EO = early onset; LO = late onset.
Early-onset Mixed and late-onset MSA not shown (n < 20).
A-B-C or A-B-C-CAA are the ND only combinations for the clinical Alzheimer’s disease (AD) and Mixed groups. TDP or Tau are the ND only combinations for FTD group.
Combinations with a prevalence of 5% or higher.